DOCETAXEL + Hydroxychloroquine + Gemcitabine for osteosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Jul 2018: Trial registered, NCT03598595
  2. 28 Jan 2019: Trial started, NCT03598595

The trials

NCT03598595: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

State
Under way
Phase
Phase 1 and Phase 2
People
31 taking part
Started
28 Jan 2019
Primary completion
31 May 2027
Arms
Treatment (hydroxychloroquine, gemcitabine, docetaxel)
Results
None posted
  1. 26 Jul 2018: Trial registered
  2. 28 Jan 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.